{"id":"lapaquistat-acetate-and-rosuvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Muscle-related adverse events"},{"rate":null,"effect":"Gastrointestinal effects"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets two distinct steps in cholesterol metabolism: lapaquistat acetate blocks the enzyme responsible for cholesterol esterification in the intestine, reducing dietary cholesterol uptake, while rosuvastatin inhibits the rate-limiting enzyme in hepatic cholesterol production. Together, they provide complementary mechanisms to lower LDL cholesterol through both reduced absorption and decreased synthesis.","oneSentence":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:18.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia / elevated LDL cholesterol"}]},"trialDetails":[{"nctId":"NCT00532311","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":411},{"nctId":"NCT00251680","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT00249912","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Hypercholesterolemia","enrollment":415},{"nctId":"NCT00249899","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":649}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-475","Crestor"],"phase":"phase_3","status":"active","brandName":"Lapaquistat acetate and rosuvastatin","genericName":"Lapaquistat acetate and rosuvastatin","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis. Used for Hypercholesterolemia / elevated LDL cholesterol.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}